Skip to main content
. 2022 Dec 1;13:935949. doi: 10.3389/fimmu.2022.935949

Figure 5.

Figure 5

NK cells from HSCT patients who have undergone an episode of CMV reactivation demonstrate early proliferation with subsequent maturation and enhanced production of cytokines. (A) The percentage of CD57+ and CD69+ on NK cells from patients following CMV reactivation (purple line and bar) or without CMV reactivation (blue line and bar). Grey lines represent the range of CD57+ and CD69+ NK cells in healthy controls. (*p<0.05, **p<0.01, ***P<0.001; Wilcoxon sign rank test for matched phenotypes). (B) Enhanced TNF-α (left panel) and IFN-γ (right panel) production from NK cells of HSCT patients following prior CMV reactivation. Data are shown as percentage of cytokine-positive NK cells following K562 stimulation. (*p<0.05**p<0.01; Anova test). (C) TNF-α (left panel) and IFN-γ (right panel) production from four NK subsets (NKG2A-/NKG2C-, NKG2A+/NKG2C-, NKG2A-/NKG2C+, NKG2A+/NKG2C+) in patients following prior CMV reactivation. Data are shown as percentage of cytokine-positive NK subsets following K562 stimulation. (*p<0.05**p<0.01***p<0.001; Anova test).